Paul Sabbatini, MD
The decision of whether or not to use frontline bevacizumab (Avastin), intraperitoneal (IP) therapy, and administer chemotherapy as a weekly dose-dense regimen or on a 3-week dosing schedule in patients with newly diagnosed ovarian cancer has been clouded by a series of conflicting clinical trials.
State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, Sabbatini clarified where the field stands regarding the use of these modalities in the frontline setting of newly diagnosed ovarian cancer.
OncLive: How has the frontline setting of ovarian cancer evolved over the years?
: We've looked at several different modalities, including IP therapy, the addition of anti-vascular therapies, as well as changing the dosing schedule of frontline therapy. Based on several randomized studies, we've come to a place where we've decided that there doesn't appear to be an advantage with IP chemotherapy. There was a robust advantage to weekly chemotherapy in the Japanese GOG3016 study, but it appeared to be less so in the subsequent GOG262 study.
... to read the full story